SEARCH

SEARCH BY CITATION

Keywords:

  • glycoprotein IIb/IIIa;
  • integrins;
  • protein structure

Abstract

  1. Top of page
  2. Abstract
  3. The extracellular domain of β3 integrins
  4. Transmembrane domain interactions regulate integrin function
  5. The structure of integrin cytosolic tails
  6. Conclusion
  7. Disclosure of Conflict of Interests
  8. References

Summary.  Integrins are a ubiquitous family of non-covalently associated α/β transmembrane heterodimers linking extracellular ligands to intracellular signaling pathways [1] [Cell, 2002; 110: 673]. Platelets contain five integrins, three β1 integrins that mediate platelet adhesion to the matrix proteins collagen, fibronectin and laminin, and the β3 integrins αvβ3 and αIIbβ3 [2] [J Clin Invest, 2005; 115: 3363]. While there are only several hundred αvβ3 molecules per platelet, αvβ3 mediates platelet adhesion to osteopontin and vitronectin in vitro [3] [J Biol Chem, 1997; 272: 8137]; whether this occurs in vivo remains unknown. By contrast, the 80 000 αIIbβ3 molecules on agonist-stimulated platelets bind fibrinogen, von Willebrand factor, and fibronectin, mediating platelet aggregation when the bound proteins crosslink adjacent platelets [2] [J Clin Invest, 2005; 115: 3363]. Although platelet integrins are poised to shift from resting to active conformations, tight regulation of their activity is essential to prevent the formation of intravascular thrombi. This review focuses on the structure and function of the intensively studied β3 integrins, in particular αIIbβ3, but reference will be made to other integrins where relevant.


The extracellular domain of β3 integrins

  1. Top of page
  2. Abstract
  3. The extracellular domain of β3 integrins
  4. Transmembrane domain interactions regulate integrin function
  5. The structure of integrin cytosolic tails
  6. Conclusion
  7. Disclosure of Conflict of Interests
  8. References

Electron microscopy (EM) of αIIbβ3 isolated from platelets revealed an 8 × 12 nm nodular headpiece containing its ligand binding site and two 18 nm flexible legs containing transmembrane (TM) and cytoplasmic domains extending from one side [4]. Further, crystal structures for the extracellular portions of αvβ3 and αIIbβ3 have revealed a complex domain structure that rearranges as the integrins switch from inactive resting to active ligand-binding conformations (Fig. 1) [5–8].

image

Figure 1.  Ribbon diagram of the structure of the extracellular portion of the αvβ3. (A) bent (inactive, resting) conformation of αvβ3 as it was present in the crystal; (B) extension of the structure to reveal its domains (active, ligand binding). Adapted from Ref. 2.

Download figure to PowerPoint

The extracellular portions of αIIb and αv are similar, consisting of an amino-terminal β-propeller domain followed by a ‘thigh’ and two ‘calf’ domains, whereas β3 is substantially more complicated [5,7]. Its amino-terminal portion consists of two tandem nested domains: a βA domain whose fold resembles that of integrin α subunit I-domains, which is inserted into a ‘hybrid’ domain whose fold is similar to an I-set Ig domain; the hybrid domain in turn is inserted into a PSI (plexin, semaphorin, integrin) domain that contains the N-terminus of β3 [7,9]. The C-terminus of the PSI domain is continuous with four tandem EGF-like repeats that make up the ‘leg’ of β3, as well as a unique carboxyl-terminal βTD domain [8]. αv and αIIb interact non-covalently with β3 via an interface between the α subunit β-propeller and the β3 βA domains that resembles the interface between the Gα and Gβ subunits of G proteins and forms the surface for ligand binding [5,7].

A surprising finding of the crystal structure of the extracellular portion of αvβ3 was a severe bend at ‘knees’ or ‘genus’ located between the first and second EGF-like repeats of β3 and the thigh and first calf domains of αv [5,10]. Recent high resolution crystal structures of the complete extracellular domain of αIIbβ3 also revealed that the inactive molecule is bent, with the 3rd and 4th EGF-like β3 domains inserted into a crevice formed by the upper β3 leg on one side, and the αIIb leg on the other side and with the αIIb β-propeller and β3 βA domains helping to form the crevice’s back [8]. Negatively-stained EM images of purified ostensibly inactive αvβ3 and αIIbβ3 are consistent with these crystal structures, whereas EM images of active αvβ3 have revealed extended molecules, similar to previous rotary-shadowed EM images of α5β1 and αIIbβ3 [4,8,11,12]. This suggests that extension is an essential feature of integrin activation [13,14]. Nonetheless, despite unequivocal evidence that the extracellular portions of αvβ3, αIIbβ3, and other integrins can assume bent configurations, the significance of this observation for integrin regulation remains controversial. The ability to engineer disulfide bonds between N-terminal and C-terminal portions of αvβ3 and αIIbβ3 in transfected cells [11] and to show decreased fluorescence resonance energy transfer (FRET) efficiency between α4β1-bound and membrane-bound fluorophores following α4β1 activation [15,16] argues strongly that both bent and extended integrin conformations occur on cell surfaces. Conversely, reconstructed electron cryomicroscopy images of low affinity αIIbβ3 [17], cryoelectron tomography of isolated αIIbβ3 incorporated into liposomes [18], intramolecular FRET of αIIbβ3 before and after platelet stimulation [19], and hydrodynamic measurements [20] suggest that inactive αIIbβ3 has either an extended or only a slightly bent conformation. The basis for these discrepant observations remains unclear. In part, it may be because of the inherent flexibility of integrin legs, the loss of conformational constraints when integrins are extracted from membranes, and the difficulty in determining detailed molecular structures at the resolution of EM.

Although the preponderance of evidence suggests integrin activation is accompanied by a shift from bent to extended conformation, extended integrins are not necessarily capable of binding ligands [11]. Ligand binding also requires that integrin headpieces shift from closed to open high affinity conformations, a process occurring when the α7 helix of the βA domain is displaced downward relative to the hybrid and PSI domains [11,21,22]. This allows the hybrid and rigidly connected PSI domains to ‘swing out’, thereby ‘opening up’ the ligand binding surface. It has been proposed that headpiece opening is the end result of a concerted ‘switchblade-like’ rearrangement of the entire heterodimer, beginning with separation of the cytoplasmic tails and TM domains, straightening and separation of the α and β subunit legs at their knees, and movement of the ligand-binding headpiece away from the membrane [8,11,23]. However, other results suggest that extension is not required for headpiece opening and that bent integrins are fully capable of binding ligands. In this case, transition from a closed to an open headpiece would be regulated by a ‘deadbolt’ composed of a loop from the β subunit βTD domain that binds to and locks the βA domain in its inactive conformation [24,25]. Allosteric re-positioning of this loop would then be sufficient to permit headpiece opening, enabling ligand binding to the bent conformation. The evidence supporting either mechanism of integrin activation is contradictory. Thus, while negatively stained EM images have been interpreted as showing fragments of fibronectin (FN) bound to bent αvβ3 extracellular domains [26], other EM images showed FN fragments bound to the top of α5β1 headpieces, as predicted if the integrin were extended [27]. Further, mutating the αMβ2 βTD domain caused constitutive αMβ2 activation [25], but mutating the βTD domains of αIIbβ3 or αvβ3 did not [28]. Nevertheless, because a deadbolt mechanism, in the absence of integrin extension, orients the ligand binding site on the headpiece toward the cell surface, rather than toward extracellular ligands, it is difficult to reconcile the geometry of a bent integrin and accessibility of its ligand binding site.

Transmembrane domain interactions regulate integrin function

  1. Top of page
  2. Abstract
  3. The extracellular domain of β3 integrins
  4. Transmembrane domain interactions regulate integrin function
  5. The structure of integrin cytosolic tails
  6. Conclusion
  7. Disclosure of Conflict of Interests
  8. References

Although rearrangement of the extracellular portion of integrins is required for ligand binding, the signals initiating this rearrangement originate in the cytosol and must be transmitted across the plasma membrane via TM helices. Truncated integrins lacking TM and cytoplasmic domains are constitutively active, implying that the deleted domains constrain integrin activity [29–31]. Moreover, ‘scissor-like’ movements of integrin legs appear to regulate integrin activity; integrins are inactive when their legs are in proximity and active when their legs separate [23,32–34].

TM helices are generally believed to serve merely as hydrophobic anchors. Thus, the observation that TM helices actively participate in the ‘scissor-like’ movements that regulate integrin function was unexpected [35]. However, TM helix-mediated protein oligomerization is a common mechanism for assembly of membrane proteins and regulation of protein function and is mediated by the presence of specific oligomerization motifs [36]. For example, glycine residues spaced four residues apart (GxxxG) in the glycophorin A TM helix (i.e., glycines separated by one turn of the TM helix) mediate the association of glycophorin A homodimers in red cell membranes by forming a tightly-packed surface of complementary ridges and grooves [37–39]. It is also noteworthy that GxxxG is the most over-represented sequence motif in databases of TM helices [40].

Polypeptides corresponding to the αIIb and β3 TM and cytoplasmic domains readily associate homomerically in phospholipid micelles [41]. Subsequently, Li et al. [35] scanned the β3 TM helix with polar Asn residues and found that replacing G708 or M701 with Asn induced spontaneous fibrinogen binding to αIIbβ3 expressed in CHO cells. The Asn replacements also induced constitutive phosphorylation of focal adhesion kinase (FAK) and the formation of αIIbβ3 patches on the cell surface, suggesting they caused αIIbβ3 clustering as well. Similarly, Vararattanavech et al. [42] found that an L686F mutation in the β2 TM domain caused constitutive αLβ2 activation and the formation of αLβ2 microclusters on the surface of transfected K562 cells. There are two plausible mechanisms to explain the effect of the Asn replacements on αIIbβ3 function. First, by enhancing the propensity of the β3 helix to oligomerize homomerically [43], the replacements could cause separation of the αIIb and β3 legs. The ability of Asn residues to enhance the tendency of β3 TM peptides to interact homomerically in vitro supports this possibility [35,44]. Second, it is possible that introducing a bulky Asn residue into a closely packed αIIb/β3 TM heterodimer could physically cause separation of the αIIb and β3 legs. In support of this possibility, replacing αIIb residues G972 or G976, the first and last residues of its GxxxG motif, with Asn induces constitutive αIIbβ3 activation, but disrupts homomeric αIIb TM helix interactions [44,45]. Taken together, these observations suggest a ‘push–pull’ mechanism for regulating αIIbβ3 activity [45]. Processes destabilizing the association of the αIIb and β3 TM helices would be expected to ‘push’αIIbβ3 to its activated conformation. Conversely, intermolecular interactions requiring separation of the αIIb and β3 TM helices, such as homo-oligomerization of the TM helices, or are more favorable when they are separated, such as ligand-induced αIIbβ3 clustering [46], would be expected to ‘pull’αIIbβ3 toward the activated state.

The ability of homomeric TM helix interactions to induce αIIbβ3 activation in cells remains to be proven [47,48], but the evidence that heterodimeric TM interactions constrain αIIbβ3 in a low affinity state is compelling. Thus, scanning the TM helices of full-length recombinant αIIbβ3 with cysteine residues results in the formation of disulfide bonds with a helical periodicity, consistent with the presence of a unique αIIb/β3 TM heterodimer [49]. Moreover, locking the heterodimer with a disulfide bond near its N-terminus prevents cell spreading on fibrinogen and adhesion-promoted tyrosine phosphorylation [50]. Conversely, peptides designed to bind tightly to the αIIb TM helix cause constitutive αIIbβ3 activation by disrupting the αIIb/β3 TM heterodimer [51,52]. Mutations along the β3 TM helix that destabilize the heterodimer have the same effect [53].

Alanine and leucine scanning mutagenesis of the αIIb TM helix revealed that the same interface mediates its homomeric and heteromeric interactions and consists of the GxxxG-containing sequence VGxxGGxxxL [44]. The β3 TM helix contains a variant of the GxxxG motif, SxxxA, but the interface mediating its homomeric and heteromeric interactions consists of the sequence LxxxVxxxIxxxG instead [54]. This observation is noteworthy because it places SxxxA on the side of the β3 helix facing away from αIIb where it could mediate the association of β3 with other proteins. Moreover, it suggests that juxtaposing the VxxxIxxxG motif of β3 and the GxxxGxxxL motif of αIIb results in a novel, closely packed, and energetically-favorable zipper-like interface (Fig. 2).

image

Figure 2.  Model of a reciprocal ‘large–small’ integrin TM heterodimer motif. The integrin heterodimer is represented as an idealized pair of helices with large spheres denoting large hydrophobic residues (leucine, isoleucine, valine) and small spheres representing small polar residues (glycine, alanine, serine) to emphasize the complementary ‘large–small’ packing observed in the heterodimer.

Download figure to PowerPoint

The structure of integrin cytosolic tails

  1. Top of page
  2. Abstract
  3. The extracellular domain of β3 integrins
  4. Transmembrane domain interactions regulate integrin function
  5. The structure of integrin cytosolic tails
  6. Conclusion
  7. Disclosure of Conflict of Interests
  8. References

Disrupting TM domain interactions alone under experimental circumstances is sufficient to cause integrin activation, but integrin activation under physiologic circumstances occurs when intracellular signals interact with integrin cytoplasmic tails. αIIbβ3 can be activated by truncating the αIIb or β3 cytoplasmic tails just after the conserved membrane proximal sequences GFFKR or LLITIHD, respectively [55]. Moreover, substituting Ala for Arg in GFFKR or Asp in LLITIHD has the same effect, whereas interchanging the residues does not [56]. While indirect, these observations suggest that the membrane-proximal portions of the cytoplasmic tails interact to form an activation-constraining ‘clasp’, a feature of which is a salt-bridge between R995 in αIIb and D723 in β3 [56]. Physiologic signals that activate αIIbβ3 might do so by disrupting the clasp. Nevertheless, neither Ulmer et al. [57] who used NMR to study the structure of the αIIb and β3 cytoplasmic tails tethered by a coiled-coil nor Li et al. [41] who analyzed the interaction of αIIb and β3 TM and cytoplasmic tail polypeptides in phospholipid micelles were able to detect the heteromeric association of these proteins.

To confirm the presence of a membrane-proximal cytosolic clasp and determine its structure, peptides corresponding to the αIIb and β3 cytoplasmic tails have been studied in aqueous buffers, dissolved in phospholipids micelles, or anchored to micelles by myristoylation [58–63]. Surprisingly, the structures resulting from these studies are substantially different. For example, Weljie et al. [60] used NMR to determine the structure of a complex that formed at low ionic strength between an 11-residue αIIb peptide and a 25-residue β3 peptide. When studied alone, neither peptide had secondary structure, but when mixed, the αIIb peptide exhibited α helical structure and two β3 conformers were detected that differed in backbone conformation (one had an elongated structure, and the other was bent back to adopt a closed L shape). A stable salt bridge at αIIb R995/β3 D723 was not detected. Vinogradova et al. [62] also used NMR to study interactions between full-length αIIb and β3 cytoplasmic tails, either as native peptides or as fusions with maltose-binding protein. When mixed in aqueous buffer, small chemical shift perturbations were detected involving N-terminal residues of β3 and N-terminal residues and C-terminal residues of αIIb, implying that these regions interact. Calculated structures indicated that the N-termini of the αIIb and β3 peptides were helical and the C-terminus of αIIb folded back to interact with the N-terminus. Further, an N-terminal α/β interface was present containing both hydrophobic and electrostatic interactions, including an electrostatic interaction between the guanidyl of αIIb R995 and the carboxyl of β3 D723. Nonetheless, the relevance of these experiments to inactive αIIbβ3 in cells remains unclear. For example, the experiments were performed at stoichiometries considerably different from the 1 : 1 stoichiometry of αIIb and β3 in native αIIbβ3. Further, interactions between αIIb and β3 were transient, rather than stable as might be expected for an activation-inhibiting clasp. Finally, the interactions were disrupted by detergent micelles, an unexpected finding for interactions occurring in the aqueous cytosol. Vinogradova et al. [63] subsequently used NMR to determine the structure of each peptide in the presence of diphosphocholine (DPC) micelles to mimic a membranous environment. Under these conditions, the N-terminus of αIIb remained helical, but the C-terminus was unable to interact with the N-terminus because the latter was embedded in lipid. β3 residues 716–721 were also embedded in lipid and residues 741 and 747 interacted with lipid as well. As a final step in agonist-stimulated αIIbβ3 activation, the FERM domain of talin binds to the β3 cytosolic tail [64]. Accordingly, Vinogradova et al. found that when the talin FERM domain and β3 peptides were mixed in aqueous buffer chemical shifts for β3 residues T720–D723 and A735–A750 were perturbed. This suggests that in vivo, talin might act by physically disrupting the membrane-proximal clasp at residue 723 and detach the mid-portion of the β3 tail from membranes as well.

Remarkably, considering its short length, the β3 tail interacts with a large number of cytosolic proteins [65]. To identify structural features responsible for these interactions, Li et al. [66] used NMR to characterize a membrane protein encompassing the β3 TM and cytoplasmic domains. Under conditions where the protein was monomeric in DPC micelles, it was found to fold into three α helices followed by a short unstructured C-terminus. The first helix corresponded to the β3 TM helix and extended into the membrane-proximal region of the cytoplasmic domain. Because the length of this helix likely exceeds that of a typical membrane bilayer, it is either oriented in the membrane in a upright fashion with the membrane-proximal region extending into the cytoplasm, buried in the membrane but tilted at an angle to accommodate its length, or buried upright in the membrane with increased membrane thickness (Fig. 3). A recent NMR analysis of the β3 TM helix embedded in lipid bicelles supports the second scenario [67]. The first helix is followed by a hinge at residues H722–D723, a second helix extending from residues K725–A735, and a turn-helix configuration characteristic of the immunoreceptor tyrosine-based ITAM motif at the C-terminal end. The NPLY motif (residues 744–747) that supports the initial interaction of the β3 tail with the talin FERM domain [68] is located in a type I β-turn just before the third helix, while the NITY motif (residues 756–759) that interacts with kindlin-3, a second FERM domain-containing protein required for αIIbβ3 activation [69], is located just after this helix. Finally, approximately 3% of the c-Src present in platelets constitutively interacts with the Arg–Ala–Thr (RGT) sequence present at the C-terminus of the β3 tail [70].

image

Figure 3.  Model of the β3 TM and cytoplasmic domains. Helices are shown as cylinders. Three different orientations of the β3 TM domain in the plasma membrane are shown. The membrane-proximal region of the cytoplasmic domain is striped. Dotted lines indicate possible interactions between helices. Adapted from Ref. 65.

Download figure to PowerPoint

Conclusion

  1. Top of page
  2. Abstract
  3. The extracellular domain of β3 integrins
  4. Transmembrane domain interactions regulate integrin function
  5. The structure of integrin cytosolic tails
  6. Conclusion
  7. Disclosure of Conflict of Interests
  8. References

Integrins, exemplified by the platelet αIIbβ3, undergo complex structural rearrangements as they shift from inactive to active conformations. Central to this process is disrupting a series of constraints imposed by conserved elements of their cytoplasmic, TM, and extracellular domains. Although the nature of many of these constraints has been determined, often at atomic-level resolution, their relative importance in regulating integrin activation remains to be clarified. Nonetheless, it is tempting to speculate that the constraints represent novel targets for manipulating integrin function for clinical benefit.

References

  1. Top of page
  2. Abstract
  3. The extracellular domain of β3 integrins
  4. Transmembrane domain interactions regulate integrin function
  5. The structure of integrin cytosolic tails
  6. Conclusion
  7. Disclosure of Conflict of Interests
  8. References
  • 1
    Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002; 110: 67387.
  • 2
    Bennett JS. Structure and function of the platelet integrin alphaIIbbeta3. J Clin Invest 2005; 115: 33639.
  • 3
    Bennett JS, Chan C, Vilaire G, Mousa SA, DeGrado WF. Agonist-activated αvβ3 on platelets and lymphocytes binds to the matrix protein osteopontin. J Biol Chem 1997; 272: 813740.
  • 4
    Weisel JW, Nagaswami C, Vilaire G, Bennett JS. Examination of the platelet membrane glycoprotein IIb/IIIa complex and its interaction with fibrinogen and other ligands by electron microscopy. J Biol Chem 1992; 267: 1663743.
  • 5
    Xiong JP, Stehle T, Diefenbach B, Zhang R, Dunker R, Scott DL, Joachimiak A, Goodman SL, Arnaout MA. Crystal structure of the extracellular segment of integrin αVβ3. Science 2001; 294: 33945.
  • 6
    Xiong JP, Stehle T, Zhang R, Joachimiak A, Frech M, Goodman SL, Arnaout MA. Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg–Gly–Asp ligand. Science 2002; 296: 1515.
  • 7
    Xiao T, Takagi J, Coller BS, Wang JH, Springer TA. Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. Nature 2004; 432: 5967.
  • 8
    Zhu J, Luo BH, Xiao T, Zhang C, Nishida N, Springer TA. Structure of a complete integrin ectodomain in a physiologic resting state and activation and deactivation by applied forces. Mol Cell 2008; 32: 84961.
  • 9
    Xiong JP, Stehle T, Goodman SL, Arnaout MA. A novel adaptation of the integrin PSI domain revealed from its crystal structure. J Biol Chem 2004; 279: 402524.
  • 10
    Shi M, Foo SY, Tan SM, Mitchell EP, Law SK, Lescar J. A structural hypothesis for the transition between bent and extended conformations of the leukocyte beta2 integrins. J Biol Chem 2007; 282: 30198206.
  • 11
    Takagi J, Petre B, Walz T, Springer T. Global conformational rearrangements in integrin extracellular domains in outside-in and inside-out signaling. Cell 2002; 110: 599611.
  • 12
    Nermut MV, Green NM, Eason P, Yamada SS, Yamada KM. Electron microscopy and structural model of human fibronectin receptor. EMBO J 1988; 7: 40939.
  • 13
    Beglova N, Blacklow SC, Takagi J, Springer TA. Cysteine-rich module structure reveals a fulcrum for integrin rearrangement upon activation. Nat Struct Biol 2002; 9: 2827.
  • 14
    Mould AP, Travis MA, Barton SJ, Hamilton JA, Askari JA, Craig SE, Macdonald PR, Kammerer RA, Buckley PA, Humphries MJ. Evidence that monoclonal antibodies directed against the integrin beta subunit plexin/semaphorin/integrin domain stimulate function by inducing receptor extension. J Biol Chem 2005; 280: 423846.
  • 15
    Chigaev A, Buranda T, Dwyer DC, Prossnitz ER, Sklar LA. FRET detection of cellular alpha4-integrin conformational activation. Biophys J 2003; 85: 395162.
  • 16
    Chigaev A, Zwartz GJ, Buranda T, Edwards BS, Prossnitz ER, Sklar LA. Conformational regulation of alpha 4 beta 1-integrin affinity by reducing agents. ‘Inside-out’ signaling is independent of and additive to reduction-regulated integrin activation. J Biol Chem 2004; 279: 3243543.
  • 17
    Adair BD, Yeager M. Three-dimensional model of the human platelet integrin alpha IIbbeta 3 based on electron cryomicroscopy and x-ray crystallography. Proc Natl Acad Sci USA 2002; 99: 1405964.
  • 18
    Ye F, Liu J, Winkler H, Taylor KA. Integrin alpha IIb beta 3 in a membrane environment remains the same height after Mn2+ activation when observed by cryoelectron tomography. J Mol Biol 2008; 378: 97686.
  • 19
    Coutinho A, Garcia C, Gonzalez-Rodriguez J, Lillo MP. Conformational changes in human integrin alphaIIbbeta3 after platelet activation, monitored by FRET. Biophys Chem 2007; 130: 7687.
  • 20
    Rocco M, Rosano C, Weisel JW, Horita DA, Hantgan RR. Integrin conformational regulation: uncoupling extension/tail separation from changes in the head region by a multiresolution approach. Structure 2008; 16: 95464.
  • 21
    Luo BH, Springer TA, Takagi J. Stabilizing the open conformation of the integrin headpiece with a glycan wedge increases affinity for ligand. Proc Natl Acad Sci USA 2003; 100: 24038.
  • 22
    Luo BH, Takagi J, Springer TA. Locking the beta3 integrin I-like domain into high and low affinity conformations with disulfides. J Biol Chem 2004; 279: 1021521.
  • 23
    Kim M, Carman CV, Springer TA. Bidirectional transmembrane signaling by cytoplasmic domain separation in integrins. Science 2003; 301: 17205.
  • 24
    Xiong JP, Stehle T, Goodman SL, Arnaout MA. New insights into the structural basis of integrin activation. Blood 2003; 102: 11559.
  • 25
    Gupta V, Gylling A, Alonso JL, Sugimori T, Ianakiev P, Xiong JP, Arnaout MA. The beta-tail domain (betaTD) regulates physiologic ligand binding to integrin CD11b/CD18. Blood 2007; 109: 351320.
  • 26
    Adair BD, Xiong JP, Maddock C, Goodman SL, Arnaout MA, Yeager M. Three-dimensional EM structure of the ectodomain of integrin {alpha}V{beta}3 in a complex with fibronectin. J Cell Biol 2005; 168: 110918.
  • 27
    Takagi J, Strokovich K, Springer TA, Walz T. Structure of integrin alpha5beta1 in complex with fibronectin. EMBO J 2003; 22: 460715.
  • 28
    Zhu J, Boylan B, Luo BH, Newman PJ, Springer TA. Tests of the extension and deadbolt models of integrin activation. J Biol Chem 2007; 282: 1191420.
  • 29
    Dana N, Fathallah DM, Arnaout MA. Expression of a soluble and functional form of the human beta 2 integrin CD11b/CD18. Proc Natl Acad Sci USA 1991; 88: 310610.
  • 30
    Peterson JA, Visentin GP, Newman PJ, Aster RH. A recombinant soluble form of the integrin alpha IIb beta 3 (GPIIb-IIIa) assumes an active, ligand-binding conformation and is recognized by GPIIb-IIIa-specific monoclonal, allo-, auto-, and drug-dependent platelet antibodies. Blood 1998; 92: 205363.
  • 31
    Mehta RJ, Diefenbach B, Brown A, Cullen E, Jonczyk A, Gussow D, Luckenbach GA, Goodman SL. Transmembrane-truncated alphavbeta3 integrin retains high affinity for ligand binding: evidence for an ‘inside-out’ suppressor? Biochem J 1998; 330: 8619.
  • 32
    Lu C, Takagi J, Springer TA. Association of the membrane proximal regions of the alpha and beta subunit cytoplasmic domains constrains an integrin in the inactive state. J Biol Chem 2001; 276: 146428.
  • 33
    Takagi J, Erickson HP, Springer TA. C-terminal opening mimics ‘inside-out’ activation of integrin α5β1. Nat Struct Biol 2001; 8: 4126.
  • 34
    Litvinov RI, Nagaswami C, Vilaire G, Shuman H, Bennett JS, Weisel JW. Functional and structural correlations of individual αIIbβ3 molecules. Blood 2004; 104: 397985.
  • 35
    Li R, Mitra N, Gratkowski H, Vilaire G, Litvinov R, Nagasami C, Weisel JW, Lear JD, DeGrado WF, Bennett JS. Activation of integrin αIIbβ3 by modulation of transmembrane helix associations. Science 2003; 300: 7958.
  • 36
    Moore DT, Berger BW, DeGrado WF. Protein–protein interactions in the membrane: sequence, structural, and biological motifs. Structure 2008; 16: 9911001.
  • 37
    Lemmon MA, Flanagan JM, Hunt JF, Adair BD, Bormann BJ, Dempsey CE, Engelman DM. Glycophorin A dimerization is driven by specific interactions between transmembrane alpha-helices. J Biol Chem 1992; 267: 76839.
  • 38
    MacKenzie KR, Prestegard JH, Engelman DM. A transmembrane helix dimer: structure and implications. Science 1997; 276: 1313.
  • 39
    Russ WP, Engelman DM. The GxxxG motif: a framework for transmembrane helix–helix association. J Mol Biol 2000; 296: 9119.
  • 40
    Senes A, Gerstein M, Engelman DM. Statistical analysis of amino acid patterns in transmembrane helices: the GxxxG motif occurs frequently and in association with beta-branched residues at neighboring positions. J Mol Biol 2000; 296: 92136.
  • 41
    Li R, Babu CR, Lear JD, Wand AJ, Bennett JS, DeGrado WF. Oligomerization of the integrin αIIbβ3: roles of the transmembrane and cytoplasmic domains. Proc Natl Acad Sci USA 2001; 98: 124627.
  • 42
    Vararattanavech A, Lin X, Torres J, Tan SM. Disruption of the integrin {alpha}L{beta}2 transmembrane domain interface by {beta}2 Thr-686 mutation activates {alpha}L{beta}2 and promotes micro-clustering of the {alpha}L subunits. J Biol Chem 2009; 284: 323949.
  • 43
    Choma C, Gratkowski H, Lear JD, DeGrado WF. Asparagine-mediated self-association of a model transmembrane helix. Nat Struct Biol 2000; 7: 1616.
  • 44
    Li R, Gorelik R, Nanda V, Law PB, Lear JD, DeGrado WF, Bennett JS. Dimerization of the transmembrane domain of Integrin αIIb subunit in cell membranes. J Biol Chem 2004; 279: 2666673.
  • 45
    Li W, Metcalf DG, Gorelik R, Li R, Mitra N, Nanda V, Law PB, Lear JD, Degrado WF, Bennett JS. A push–pull mechanism for regulating integrin function. Proc Natl Acad Sci USA 2005; 102: 14249.
  • 46
    Fox JE, Shattil SJ, Kinlough-Rathbone RL, Richardson M, Packham MA, Sanan DA. The platelet cytoskeleton stabilizes the interaction between αIIbβ3 and its ligand and induces selective movements of ligand- occupied integrin. J Biol Chem 1996; 271: 700411.
  • 47
    Kim M, Carman CV, Yang W, Salas A, Springer TA. The primacy of affinity over clustering in regulation of adhesiveness of the integrin {alpha}L{beta}2. J Cell Biol 2004; 167: 124153.
  • 48
    Luo BH, Carman CV, Takagi J, Springer TA. Disrupting integrin transmembrane domain heterodimerization increases ligand binding affinity, not valency or clustering. Proc Natl Acad Sci USA 2005; 102: 367984.
  • 49
    Luo BH, Springer TA, Takagi J. A specific interface between integrin transmembrane helices and affinity for ligand. PLoS Biol 2004; 2: 77686.
  • 50
    Zhu J, Carman CV, Kim M, Shimaoka M, Springer TA, Luo BH. Requirement of alpha and beta subunit transmembrane helix separation for integrin outside-in signaling. Blood 2007; 110: 247583.
  • 51
    Yin H, Litvinov RI, Vilaire G, Zhu H, Li W, Caputo GA, Moore DT, Lear JD, Weisel JW, Degrado WF, Bennett JS. Activation of platelet alphaIIbbeta3 by an exogenous peptide corresponding to the transmembrane domain of alphaIIb. J Biol Chem 2006; 281: 3673241.
  • 52
    Yin H, Slusky JS, Berger BW, Walters RS, Vilaire G, Litvinov RI, Lear JD, Caputo GA, Bennett JS, DeGrado WF. Computational design of peptides that target transmembrane helices. Science 2007; 315: 181722.
  • 53
    Partridge AW, Liu S, Kim S, Bowie JU, Ginsberg MH. Transmembrane domain helix packing stabilizes integrin alphaIIbbeta3 in the low affinity state. J Biol Chem 2005; 280: 7294300.
  • 54
    Berger BW, Span L, Kulp DW, Billings P, Zhu H, DeGrado WF, Bennett JS. A conserved transmembrane domain interface regulated integrin function. Blood 2008; 112: 986a.
  • 55
    O’Toole TE, Katagiri Y, Faull RJ, Peter K, Tamura R, Quaranta V, Loftus JC, Shattil SJ, Ginsberg MH. Integrin cytoplasmic domains mediate inside-out signal transduction. J Cell Biol 1994; 124: 104759.
  • 56
    Hughes PE, Diaz-Gonzales F, Leong L, Wu C, McDonald JA, Shattil SJ, Ginsberg MH. Breaking the integrin hinge. A defined structural constraint regulates integrin signaling. J Biol Chem 1996; 271: 65714.
  • 57
    Ulmer TS, Yaspan B, Ginsberg MH, Campbell ID. NMR analysis of structure and dynamics of the cytosolic tails of integrin alpha IIb beta 3 in aqueous solution. Biochemistry 2001; 40: 7498508.
  • 58
    Haas TA, Plow EF. The cytoplasmic domain of alphaIIb beta3. A ternary complex of the integrin alpha and beta subunits and a divalent cation. J Biol Chem 1996; 271: 601726.
  • 59
    Vallar L, Melchior C, Plancon S, Drobecq H, Lippens G, Regnault V, Kieffer N. Divalent cations differentially regulate integrin αIIb cytoplasmic tail binding to β3 and to calcium- and integrin-binding protein. J Biol Chem 1999; 274: 1725766.
  • 60
    Weljie AM, Hwang PM, Vogel HJ. Solution structures of the cytoplasmic tail complex from platelet integrin alpha IIb- and beta 3-subunits. Proc Natl Acad Sci USA 2002; 99: 587883.
  • 61
    Vinogradova O, Haas T, Plow EF, Qin J. A structural basis for integrin activation by the cytoplasmic tail of the alpha IIb-subunit. Proc Natl Acad Sci USA 2000; 97: 14505.
  • 62
    Vinogradova O, Velyvis A, Velyviene A, Hu B, Haas T, Plow E, Qin J. A structural mechanism of integrin αIIbβ3 ‘inside-out’ activation as regulated by its cytoplasmic face. Cell 2002; 110: 58797.
  • 63
    Vinogradova O, Vaynberg J, Kong X, Haas TA, Plow EF, Qin J. Membrane-mediated structural transitions at the cytoplasmic face during integrin activation. Proc Natl Acad Sci USA 2004; 101: 40949.
  • 64
    Tadokoro S, Shattil SJ, Eto K, Tai V, Liddington RC, De Pereda JM, Ginsberg MH, Calderwood DA. Talin binding to integrin beta tails: a final common step in integrin activation. Science 2003; 302: 1036.
  • 65
    Buensuceso CS, Arias-Salgado EG, Shattil SJ. Protein–protein interactions in platelet alphaIIbbeta3 signaling. Semin Thromb Hemost 2004; 30: 42739.
  • 66
    Li R, Babu CR, Valentine K, Lear JD, Wand AJ, Bennett JS, DeGrado WF. Characterization of the monomeric form of the transmembrane and cytoplasmic domains of the integrin beta 3 subunit by NMR spectroscopy. Biochemistry 2002; 41: 1561824.
  • 67
    Lau TL, Partridge AW, Ginsberg MH, Ulmer TS. Structure of the integrin beta3 transmembrane segment in phospholipid bicelles and detergent micelles. Biochemistry 2008; 47: 400816.
  • 68
    Wegener KL, Partridge AW, Han J, Pickford AR, Liddington RC, Ginsberg MH, Campbell ID. Structural basis of integrin activation by talin. Cell 2007; 128: 17182.
  • 69
    Moser M, Nieswandt B, Ussar S, Pozgajova M, Fassler R. Kindlin-3 is essential for integrin activation and platelet aggregation. Nat Med 2008; 14: 32530.
  • 70
    Arias-Salgado EG, Lizano S, Sarkar S, Brugge JS, Ginsberg MH, Shattil SJ. Src kinase activation by direct interaction with the integrin beta cytoplasmic domain. Proc Natl Acad Sci USA 2003; 100: 13298302.